{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:55Z","timestamp":1786982755669,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40261-021-01081-y","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T04:03:27Z","timestamp":1632197007000},"page":"955-965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-4835","authenticated-orcid":false,"given":"Laurence","family":"Brunet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4337-6222","authenticated-orcid":false,"given":"Patrick","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1556-811X","authenticated-orcid":false,"given":"Jennifer S.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Wohlfeiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-784X","authenticated-orcid":false,"given":"Gregory P.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"1081_CR1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. 2018. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf. Accessed 25 Oct 2018."},{"issue":"5","key":"1081_CR2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"R Cooper","year":"2010","unstructured":"Cooper R, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496\u2013505. https:\/\/doi.org\/10.1086\/655681.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1081_CR3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1179\/1945577115Y.0000000004","volume":"16","author":"LG Hemkens","year":"2015","unstructured":"Hemkens LG, Ewald H, Santini-Oliveira M, Buhler JE, Vuichard D, Schandelmaier S, et al. Comparative effectiveness of tenofovir in treatment-naive HIV-infected patients: systematic review and meta-analysis. HIV Clin Trials. 2015;16(5):178\u201389. https:\/\/doi.org\/10.1179\/1945577115Y.0000000004.","journal-title":"HIV Clin Trials"},{"issue":"3","key":"1081_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/COH.0000000000000248","volume":"11","author":"PM Grant","year":"2016","unstructured":"Grant PM, Cotter AG. Tenofovir and bone health. Curr Opin HIV AIDS. 2016;11(3):326\u201332. https:\/\/doi.org\/10.1097\/COH.0000000000000248.","journal-title":"Curr Opin HIV AIDS"},{"issue":"15","key":"1081_CR5","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1097\/qad.0000000000002699","volume":"34","author":"V Pilkington","year":"2020","unstructured":"Pilkington V, Hughes SL, Pepperrell T, McCann K, Gotham D, Pozniak AL, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. AIDS. 2020;34(15):2259\u201368. https:\/\/doi.org\/10.1097\/qad.0000000000002699.","journal-title":"AIDS"},{"issue":"11","key":"1081_CR6","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","volume":"24","author":"M Tungsiripat","year":"2010","unstructured":"Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010;24(11):1781\u20134. https:\/\/doi.org\/10.1097\/QAD.0b013e32833ad8b4.","journal-title":"AIDS"},{"issue":"2","key":"1081_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3851\/IMP1518","volume":"15","author":"PA Randell","year":"2010","unstructured":"Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir Ther. 2010;15(2):227\u201333. https:\/\/doi.org\/10.3851\/IMP1518.","journal-title":"Antivir Ther"},{"issue":"3","key":"1081_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1093\/cid\/civ296","volume":"61","author":"JR Santos","year":"2015","unstructured":"Santos JR, Saumoy M, Curran A, Bravo I, Llibre JM, Navarro J, et al. The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind placebo-controlled trial. Clin Infect Dis. 2015;61(3):403\u20138. https:\/\/doi.org\/10.1093\/cid\/civ296.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1081_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jama.292.2.191","volume":"292","author":"JE Gallant","year":"2004","unstructured":"Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir df vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191\u2013201. https:\/\/doi.org\/10.1001\/jama.292.2.191.","journal-title":"JAMA"},{"issue":"6","key":"1081_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3851\/IMP2305","volume":"17","author":"G Behrens","year":"2012","unstructured":"Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H, et al. Switching to tenofovir\/emtricitabine from abacavir\/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17(6):1011\u201320. https:\/\/doi.org\/10.3851\/IMP2305.","journal-title":"Antivir Ther"},{"issue":"2","key":"1081_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/QAD.0b013e328341f925","volume":"25","author":"HM Crane","year":"2011","unstructured":"Crane HM, Grunfeld C, Willig JH, Mugavero MJ, Van Rompaey S, Moore R, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS. 2011;25(2):185\u201395. https:\/\/doi.org\/10.1097\/QAD.0b013e328341f925.","journal-title":"AIDS"},{"issue":"3","key":"1081_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/cid\/ciy083","volume":"67","author":"DV Glidden","year":"2018","unstructured":"Glidden DV, Mulligan K, McMahan V et al. Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin Infect Dis. 2018;67(3):411\u20139.","journal-title":"Clin Infect Dis."},{"issue":"6","key":"1081_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/apt.14218","volume":"46","author":"AA Shaheen","year":"2017","unstructured":"Shaheen AA, AlMattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, et al. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers. Aliment Pharmacol Ther. 2017;46(6):599\u2013604. https:\/\/doi.org\/10.1111\/apt.14218.","journal-title":"Aliment Pharmacol Ther"},{"key":"1081_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","volume":"119","author":"E De Clercq","year":"2016","unstructured":"De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1\u20137. https:\/\/doi.org\/10.1016\/j.bcp.2016.04.015.","journal-title":"Biochem Pharmacol"},{"key":"1081_CR15","unstructured":"Orkin C, Castelli F, Yazdanpanah Y, Rockstroh J, Brinson C, DiPerri G et al. PEB104. Cardiovascular disease risk assessments and fasting lipid changes in virologically suppressed patients randomized to switch to tenofovir alafenamide versus continuing tenofovir disoproxil fumarate. In: 22nd International AIDS Conference; 23\u201227 July; Amsterdam, the Netherlands 2018."},{"issue":"2","key":"1081_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/QAI.0000000000001344","volume":"75","author":"F Raffi","year":"2017","unstructured":"Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, et al. Brief report: long-term (96-Week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acq Immune Def Syndr (1999). 2017;75(2):226\u201331. https:\/\/doi.org\/10.1097\/QAI.0000000000001344.","journal-title":"J Acq Immune Def Syndr (1999)."},{"issue":"1","key":"1081_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","volume":"16","author":"A Mills","year":"2016","unstructured":"Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43\u201352. https:\/\/doi.org\/10.1016\/S1473-3099(15)00348-5.","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 8","key":"1081_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25187","volume":"21","author":"L Gazzola","year":"2018","unstructured":"Gazzola L, Tagliaferri G, Mondatore D, De Bona A, Borsino C, Bini T, et al. Increases in lipid profile after switch from TDF to TAF-based HAART regimens in a cohort of HIV-positive patients: is it clinically relevant? J Int AIDS Soc. 2018;21(Suppl 8):e25187. https:\/\/doi.org\/10.1002\/jia2.25187.","journal-title":"J Int AIDS Soc."},{"issue":"Suppl 1","key":"1081_CR19","doi-asserted-by":"publisher","first-page":"S665-S","DOI":"10.1093\/ofid\/ofy210.1901","volume":"5","author":"E Ewers","year":"2018","unstructured":"Ewers E, Won S, Okulicz J, Ferguson T, Deiss R, Maves R, et al. 2248. Changes in lipid profiles for patients to tenofovir alafenamide (TAF)-containing regimens: perspectives from a military HIV-positive cohort. Open Forum Infect Dis. 2018;5(Suppl 1):S665-S. https:\/\/doi.org\/10.1093\/ofid\/ofy210.1901.","journal-title":"Open Forum Infect Dis"},{"issue":"15","key":"1081_CR20","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1097\/qad.0000000000002350","volume":"33","author":"A Milinkovic","year":"2019","unstructured":"Milinkovic A, Berger F, Arenas-Pinto A, Mauss S. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS. 2019;33(15):2387\u201391. https:\/\/doi.org\/10.1097\/qad.0000000000002350.","journal-title":"AIDS"},{"issue":"10","key":"1081_CR21","doi-asserted-by":"publisher","first-page":"ofz414","DOI":"10.1093\/ofid\/ofz414","volume":"6","author":"JJ Schafer","year":"2019","unstructured":"Schafer JJ, Sassa KN, O\u2019Connor JR, Shimada A, Keith SW, DeSimone JA. Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide. Open Forum Infect Dis. 2019;6(10):ofz414. https:\/\/doi.org\/10.1093\/ofid\/ofz414.","journal-title":"Open Forum Infect Dis"},{"key":"1081_CR22","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.2147\/DDDT.S274307","volume":"14","author":"N Squillace","year":"2020","unstructured":"Squillace N, Ricci E, Menzaghi B, De Socio GV, Passerini S, Martinelli C, et al. The effect of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on liver enzymes, glucose, and lipid profile. Drug Des Devel Ther. 2020;14:5515\u201320. https:\/\/doi.org\/10.2147\/DDDT.S274307.","journal-title":"Drug Des Devel Ther."},{"issue":"25, Part B","key":"1081_CR23","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25, Part B):2889\u2013934. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.002.","journal-title":"J Am Coll Cardiol"},{"key":"1081_CR24","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. 2019. https:\/\/files.aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf. Accessed 29 Apr 2020."},{"key":"1081_CR25","unstructured":"U.S. Department of Health and Human Services. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 2001. https:\/\/www.nhlbi.nih.gov\/files\/docs\/guidelines\/atp3xsum.pdf. Accessed 5 June 2019."},{"issue":"25, Part B","key":"1081_CR26","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff","year":"2014","unstructured":"Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB, Gibbons R, et al. ACC\/AHA guideline on the assessment of\u00a0cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25, Part B):2935\u201359. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.005.","journal-title":"J Am Coll Cardiol"},{"key":"1081_CR27","volume-title":"UpToDate","author":"PW Wilson","year":"2019","unstructured":"Wilson PW. Cardiovascular disease risk assessment for primary prevention: Our approach. In: Post TW, editor. UpToDate. Waltham: UpToDate; 2019."},{"issue":"9987","key":"1081_CR28","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","volume":"385","author":"PE Sax","year":"2015","unstructured":"Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(15)60616-X.","journal-title":"Lancet"},{"issue":"2","key":"1081_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/qai.0000000000001350","volume":"75","author":"JR Arribas","year":"2017","unstructured":"Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, et al. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E\/C\/F) for initial HIV-1 treatment week 144 results. JAIDS J Acq Immune Def Syndr. 2017;75(2):211\u20138. https:\/\/doi.org\/10.1097\/qai.0000000000001350.","journal-title":"JAIDS J Acq Immune Def Syndr"},{"issue":"5","key":"1081_CR30","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/S2352-3018(17)30031-0","volume":"4","author":"C Orkin","year":"2017","unstructured":"Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. The Lancet HIV. 2017;4(5):e195\u2013204. https:\/\/doi.org\/10.1016\/S2352-3018(17)30031-0.","journal-title":"The Lancet HIV."},{"issue":"4","key":"1081_CR31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/bcpt.13161","volume":"124","author":"P Cid-Silva","year":"2019","unstructured":"Cid-Silva P, Fernandez-Bargiela N, Margusino-Framinan L, Balboa-Barreiro V, Mena-De-Cea A, Lopez-Calvo S, et al. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Basic Clin Pharmacol Toxicol. 2019;124(4):479\u201390. https:\/\/doi.org\/10.1111\/bcpt.13161.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"8","key":"1081_CR32","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/qad.0000000000002541","volume":"34","author":"A Lacey","year":"2020","unstructured":"Lacey A, Savinelli S, Barco EA, Macken A, Cotter AG, Sheehan G, et al. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV. AIDS. 2020;34(8):1161\u201370. https:\/\/doi.org\/10.1097\/qad.0000000000002541.","journal-title":"AIDS"},{"issue":"10","key":"1081_CR33","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/hiv.12530","volume":"18","author":"P Echeverria","year":"2017","unstructured":"Echeverria P, Bonjoch A, Puig J, Ornella A, Clotet B, Negredo E. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia. HIV Med. 2017;18(10):782\u20136. https:\/\/doi.org\/10.1111\/hiv.12530.","journal-title":"HIV Med"},{"issue":"4","key":"1081_CR34","doi-asserted-by":"publisher","first-page":"e25702","DOI":"10.1002\/jia2.25702","volume":"24","author":"PW Mallon","year":"2021","unstructured":"Mallon PW, Brunet L, Hsu RK, Fusco JS, Mounzer KC, Prajapati G, et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc. 2021;24(4):e25702. https:\/\/doi.org\/10.1002\/jia2.25702.","journal-title":"J Int AIDS Soc"},{"key":"1081_CR35","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4853","author":"B Surial","year":"2021","unstructured":"Surial B, Mugglin C, Calmy A, Cavassini M, Gunthard HF, Stockle M, et al. Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV\u202f: a cohort study. Ann Intern Med. 2021. https:\/\/doi.org\/10.7326\/M20-4853.","journal-title":"Ann Intern Med"},{"key":"1081_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/0956462420983699","author":"M \u0141omiak","year":"2021","unstructured":"\u0141omiak M, St\u0119pnicki J, Miku\u0142a T, Wierci\u0144ska-Drapa\u0142o A. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group. Int J STD & AIDS. 2021. https:\/\/doi.org\/10.1177\/0956462420983699.","journal-title":"Int J STD & AIDS."},{"issue":"1","key":"1081_CR37","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/qai.0000000000001454","volume":"76","author":"SG Kelly","year":"2017","unstructured":"Kelly SG, Krueger KM, Grant JL, Penugonda S, Feinstein MJ, Taiwo BO, et al. Statin prescribing practices in the comprehensive care for HIV-infected patients. JAIDS J Acq Immune Def Synd. 2017;76(1):e26\u20139. https:\/\/doi.org\/10.1097\/qai.0000000000001454.","journal-title":"JAIDS J Acq Immune Def Synd"},{"issue":"1","key":"1081_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3325\/cmj.2015.56.14","volume":"56","author":"J Begovac","year":"2015","unstructured":"Begovac J, Dragovic G, Viskovic K, Kusic J, Perovic Mihanovic M, Lukas D, et al. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy. Croat Med J. 2015;56(1):14\u201323.","journal-title":"Croat Med J"},{"issue":"3","key":"1081_CR39","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/cid\/ciw289","volume":"63","author":"ME Clement","year":"2016","unstructured":"Clement ME, Park LP, Navar AM, Okeke NL, Pencina MJ, Douglas PS, et al. Statin utilization and recommendations among HIV- and HCV-infected veterans: a cohort study. Clin Infect Dis. 2016;63(3):407\u201313. https:\/\/doi.org\/10.1093\/cid\/ciw289.","journal-title":"Clin Infect Dis"},{"key":"1081_CR40","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6113.1000499","author":"S Bagchi","year":"2015","unstructured":"Bagchi S, Patel P, Faramand R, Burrowes S, Hossain MB, Kottilil S, et al. Underutilization of statins for prevention of cardiovascular disease among primarily African-American HIV-infected patients. J AIDS Clin Res. 2015. https:\/\/doi.org\/10.4172\/2155-6113.1000499.","journal-title":"J AIDS Clin Res."},{"issue":"11","key":"1081_CR41","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1089\/apc.2017.0145","volume":"31","author":"JV Todd","year":"2017","unstructured":"Todd JV, Cole SR, Wohl DA, Simpson RJJ, Jonsson Funk M, Brookhart MA, et al. Underutilization of statins when indicated in HIV-seropositive and seronegative women. AIDS Patient Care STDS. 2017;31(11):447\u201354. https:\/\/doi.org\/10.1089\/apc.2017.0145.","journal-title":"AIDS Patient Care STDS"},{"key":"1081_CR42","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.5888\/pcd10.120083","volume":"10","author":"KA Lichtenstein","year":"2013","unstructured":"Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi E, et al. Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chronic Dis. 2013;10:E10. https:\/\/doi.org\/10.5888\/pcd10.120083.","journal-title":"Prev Chronic Dis"},{"issue":"2","key":"1081_CR43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/1741826711398431","volume":"19","author":"N Reinsch","year":"2012","unstructured":"Reinsch N, Neuhaus K, Esser S, Potthoff A, Hower M, Mostardt S, et al. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol. 2012;19(2):267\u201374. https:\/\/doi.org\/10.1177\/1741826711398431.","journal-title":"Eur J Prev Cardiol"},{"issue":"14","key":"1081_CR44","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1097\/QAD.0000000000000360","volume":"28","author":"MV Zanni","year":"2014","unstructured":"Zanni MV, Fitch KV, Feldpausch M, Han A, Lee H, Lu MT, et al. 2013 American College of Cardiology\/American Heart Association and 2004 adult treatment panel III cholesterol guidelines applied to HIV-infected patients with\/without subclinical high-risk coronary plaque. AIDS (London, England). 2014;28(14):2061\u201370. https:\/\/doi.org\/10.1097\/QAD.0000000000000360.","journal-title":"AIDS (London, England)."},{"issue":"5","key":"1081_CR45","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/QAI.0000000000000908","volume":"71","author":"A Pozniak","year":"2016","unstructured":"Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study (1999). J Acq Immune Def Syndr. 2016;71(5):530\u20137. https:\/\/doi.org\/10.1097\/QAI.0000000000000908.","journal-title":"J Acq Immune Def Syndr"},{"issue":"24","key":"1081_CR46","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.002.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1081_CR47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s11904-021-00567-w","volume":"18","author":"AC Achhra","year":"2021","unstructured":"Achhra AC, Lyass A, Borowsky L, Bogorodskaya M, Plutzky J, Massaro JM, et al. Assessing cardiovascular risk in people living with HIV: current tools and limitations. Curr HIV\/AIDS Rep. 2021;18(4):271\u20139. https:\/\/doi.org\/10.1007\/s11904-021-00567-w.","journal-title":"Curr HIV\/AIDS Rep"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01081-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01081-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01081-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:33:05Z","timestamp":1635553985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01081-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1081"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01081-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]},"assertion":[{"value":"2 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LB, JSF and GPF are employees of Epividian, Inc. Epividian has had research funded by Merck & Co., ViiV Healthcare, Janssen Pharmaceuticals, Gilead Sciences, and AIDS Healthcare Foundation. PM has received research grants from ViiV Healthcare, Gilead Sciences and Janssen Cilag; speaker honoraria from ViiV Healthcare, Gilead Sciences, Janssen Cilag, BMS. and MSD; and advisory board participation from ViiV Healthcare, Gilead Sciences, Janssen Cilag, BMS and MSD. MBW has participated in post-conference advisory boards for the Conference on Retroviruses and Opportunistic Infections (CROI) and International AIDS Conference (IAC) and also serves as a principal investigator on ViiV Healthcare clinical trials but does not receive personal compensation for this work, which goes directly to the AIDS Healthcare Foundation. MBW is also a member of the Epidemiology and Clinical Advisory Board for Epividian. AB and GP are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"OPERA\u00ae complies with all HIPAA and HITECH requirements and receives annual institutional review board approval by Advarra IRB, including a waiver of informed consent and authorization for use of protected health information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and analyzed during the current study are not publicly available due to their proprietary nature, but access may be granted with parties agreeing to privacy restrictions and technological specifications and requirements.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Access to codes may be granted upon request with parties agreeing to privacy restrictions and technological specifications and requirements.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LB, PM, JSF, GP and AB contributed to the study conception and design. JSF, MBW and GPF contributed to the acquisition of data. LB performed the statistical analyses. All authors contributed to the interpretation of results. LB wrote the first draft of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}